Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate

Journal of Medicinal Chemistry

Volumn 55, Issue 4, 2012, Pages 1500-1510

  Chhikara, Bhupender S ^a   Mandal, Deendayal ^a   Parang, Keykavous ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 [( TETRADECANOYL)SUCCINYL]DOXORUBICIN; 14 [(N DODECYLAMIDO)SUCCINYL]DOXORUBICIN; 14 [(N HEXADECYLAMIDO)SUCCINYL]DOXORUBICIN; 14 [(N TETRADECYLAMIDO)SUCCINYL]DOXORUBICIN; 14 DOXORUBICINYLSUCCINATE ESTER; DOXORUBICIN; DOXORUBICIN HEMISUCCINATE; DOXORUBICIN SUCCINATE; HYDROXYL GROUP; N FMOC DOXORUBICIN; N FMOC DOXORUBICIN 14 HEMISUCCINATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONJUGATION; CYTOPLASM; CYTOTOXICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; LIPOPHILICITY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; HUMANS; HYDROLYSIS; INTRACELLULAR SPACE; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS;

EID: 84857415410     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201653u     Document Type: Article

References (34)

1. Garattini, S. Pharmacokinetics in cancer chemotherapy Eur. J. Cancer 2007, 43, 271-282 (Pubitemid 46151699)
2. Takakura, Y.; Hashida, M. Macromolecular drug carrier systems in cancer chemotherapy: Macromolecular prodrugs Crit. Rev. Oncol/Hematol. 1995, 18, 207-231
3. Mohanty, C.; Sahoo, S. K. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation Biomaterials 2010, 31, 6597-6611
4. Vincenzi, B.; Frezza, A. M.; Santini, D.; Tonini, G. New therapies in soft tissue sarcoma Expert Opin. Emerging Drugs 2010, 15, 237-248
5. Nori, A.; Kopecek, J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy Adv. Drug Delivery Rev. 2005, 57, 609-636 (Pubitemid 40267695)
6. Tang, Y.; McGoron, A. J. Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells J. Photochem. Photobiol. B: Biol. 2009, 97, 138-144
7. Hu, F. Q.; Wu, X. L.; Du, Y. Z.; You, J.; Yuan, H. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin Eur. J. Pharm. Biopharm. 2008, 69, 117-125 (Pubitemid 351467161)
8. Raoul, J. L.; Heresbach, D.; Bretagne, J. F.; Ferrer, D. B.; Duvauferrier, R.; Bourguet, P.; Messner, M.; Gosselin, M. Chemoembolization of hepatocellular carcinomas a study of the biodistribution and pharmacokinetics of doxorubicin Cancer 1992, 70, 585-590
9. Rahman, A.; Carmichael, D.; Harris, M.; Roh, J. K. Comparative pharmacokinetics of free doxorubicin and doxirubicin entrapped in cardiolipin liposomes Cancer Res. 1986, 46, 2295-2299 (Pubitemid 16120685)
10. Tang, X. H.; Xie, P.; Ding, Y.; Chu, L. Y.; Hou, J. P.; Yang, J. L.; Song, X.; Xie, Y. M. Synthesis, characterization, and in vitro and in vivo evaluation of a novel pectin-adriamycin conjugate Bioorg. Med. Chem. 2010, 18, 1599-1609
11. Riganti, C.; Voena, C.; Kopecka, J.; Corsetto, P. A.; Montorfano, G.; Enrico, E.; Costamagna, C.; Rizzo, A. M.; Ghigo, D.; Bosia, A. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells Mol. Pharmaceutics 2011, 8, 683-700
12. Takemura, G.; Fujiwara, H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management Prog. Cardiovasc. Dis. 2007, 49, 330-352 (Pubitemid 46295436)
13. Ayla, S.; Seckin, I.; Tanriverdi, G.; Cengiz, M.; Eser, M.; Soner, B. C.; Oktem, G. Doxorubicin induced nephrotoxicity: Protective effect of nicotinamide. Int. J. Cell Biol. 2011, 390238. Epub 2011, Jun 16
14. Elsadek, B.; Graeser, R.; Wamecke, A.; Unger, C.; Saleem, T.; El-Melegy, N. Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen ACS Med. Chem. Lett. 2010, 1, 234-238
15. Chaudhuri, P.; Paraskar, A.; Soni, S.; Mashelkar, R. A.; Sengupta, S. Fullerenol-cytotoxic conjugates for cancer chemotherapy ACS Nano 2009, 3, 2505-2514
16. Dhar, S.; Reddy, E. M.; Shiras, A.; Pokharkar, V.; Prasad, B. L. Natural gum reduced/stabilized gold nanoparticles for drug delivery formulations Chemistry 2008, 14, 10244-10250
17. Kumar, S. A.; Peter, Y. A.; Nadeau, J. L. Facile biosynthesis, separation and conjugation of gold nanoparticles to doxorubicin Nanotechnology 2008, 19, 495101
18. You, J.; Zhang, G.; Li, C. Exceptioanlly high payload of doxorubicin in hollow gold nanosphere for near-infrared light-triggered drug release ACS Nano 2010, 4, 1033-1041
19. Alba, E.; Ruiz-Borrego, M.; Margeli, M.; Rodriguez-Lescure, A.; Sanchez-Rovira, P.; Ruiz, A.; Mel-Lorenzo, J. R.; Ramos-Vazquez, M.; Ribelles, N.; Calvo, E.; Casado, A.; Marquez, A.; Vicente, D.; Garcia-Saenz, J. A.; Martin, M. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study Breast Cancer Res. Treat. 2010, 122, 169-176
20. Rusetskaya, N. V.; Lukyanova, N. Y.; Chekhun, V. F. Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin Exp. Oncol. 2009, 31, 140-143
21. Huober, J.; Fett, W.; Nusch, A.; Neise, M.; Schmidt, M.; Wischnik, A.; Gerhardt, S.; Goehler, T.; Luck, H. J.; Rost, A. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer BMC Cancer 2010, 10, 2
22. Stevens, P. J.; Lee, R. J. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes Anticancer Res. 2003, 23, 439-442 (Pubitemid 36358548)
23. Abraham, S. A.; Waterhouse, D. N.; Mayer, L. D.; Cullis, P. R.; Madden, T. D.; Bally, M. B. The liposomal formulation of doxorubicin Methods Enzymol. 2005, 391, 71-97 (Pubitemid 40254030)
24. Meyer-Losic, F.; Quinonero, J.; Dubois, V.; Alluis, B.; Dechambre, M.; Michel, M.; Cailler, F.; Fernandez, A. M.; Trouet, A.; Kearsey, J. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell) J. Med. Chem. 2006, 49, 6908-6916 (Pubitemid 44749756)
25. Ché, C.; Yang, G.; Thiot, C.; Lacoste, M.-C.; Currie, J.-C.; Demeule, M.; Régina, A.; Béliveau, R.; Castaigne, J.-P. New angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration J. Med. Chem. 2010, 53, 2814-2824
26. Zhu, S.; Hong, M.; Zhang, L.; Tang, G.; Jiang, Y.; Pei, Y. PEGylated PAMAM dendrimer-doxorubicin conjugates: In vitro evaluation and in vivo tumor accumulation Pharm. Res. 2010, 27, 161-174
27. Varaprasad, K.; Ravindra, S.; Reddy, N. N.; Vimala, K.; Raju, K. M. Design and development of temperature sensitive porous poly(NIPAAm-AMPS) hydrogels for drug release of doxorubicin-a cancer chemotherapy drug J. Appl. Polym. Sci. 2010, 116, 3593-3602
28. Ibsen, S.; Zahavy, E.; Wrasdilo, W.; Berns, M.; Chan, M.; Esener, S. A novel doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy Pharm. Res. 2010, 27, 1848-1860
29. Chhikara, B. S.; Parang, K. Development of cytarabine prodrugs and delivery systems for leukemia treatment Expert Opin. Drug Delivery 2010, 7, 1399-1414
30. Wang, Y.; Li, L.; Jiang, W.; Yang, Z.; Zhang, Z. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate Bioorg. Med. Chem. Lett. 2006, 16, 2974-2977
31. Kratz, F. DOXO-EMCH (INNO-206):The first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin. Invest. Drugs 2007, 16, 855-866 (Pubitemid 46882358)
32. Chhikara, B. S.; St. Jean, N.; Mandal, D.; Kumar, A.; Parang, K. Fatty acyl amide derivatives of doxorubicin: Synthesis and in vitro anticancer activities Eur. J. Med. Chem. 2011, 46, 2037-2042
33. Patel, D. J.; Kozlowski, S. A.; Rice, J. A. Hydrogen bonding, overlap geometry, and sequence specificity in anthracycline antitumor antibiotic.DNA complexes in solution Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 3333-3337 (Pubitemid 11059284)
34. Quigley, G. J.; Wang, A. H.; Ughetto, G.; van der Marel, G.; van Boom, J. H.; Rich, A. Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG) Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 7204-7208 (Pubitemid 11189441)